Bioventus (BVS) Cash from Discontinued Operations (2022 - 2023)
Bioventus' (BVS) quarterly Cash from Discontinued Operations came in at -$2.2 million in Q2 2023, down 70.65% quarter-over-quarter from -$1.3 million in Q4 2022.
Powered by 
Analysis
Bioventus (BVS) Cash from Discontinued Operations (2022 - 2023) Analysis & Trends
Bioventus (BVS) has reported Cash from Discontinued Operations for 2 consecutive years, with -$2.2 million the latest figure, recorded in Q2 2023.
- For the quarter ending Q2 2023, Cash from Discontinued Operations changed N/A year-over-year to -$2.2 million; the trailing twelve-month figure through Dec 2023 stood at -$2.2 million (down 1.83% YoY), and the FY2023 full-year result was -$2.2 million, down 1.83% from the prior year.
- Cash from Discontinued Operations retreated to -$2.2 million in Q2 2023 per BVS's latest filing, from -$1.3 million in the prior quarter.
- Across five years, Cash from Discontinued Operations topped out at -$859000.0 in Q4 2022 and bottomed at -$2.2 million in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | - |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | - |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | - |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | - |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | - |
| 9 | Steris | 21.90 Bn | 21.43 Bn | 684.20 Mn | - |
| 10 | Bioventus | 1.18 Bn | 1.20 Bn | 105.67 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 1, 2023 | -2.17 Mn |
| Dec 31, 2022 | -1.27 Mn |
| Oct 1, 2022 | -859,000.00 |